Early breast cancer immunotherapy study stopped short
NCT ID NCT05180006
First seen Jan 06, 2026 · Last updated May 15, 2026 · Updated 14 times
Summary
This study looked at whether giving a short course of immunotherapy (atezolizumab, alone or with other drugs) before standard treatment could boost the immune system's attack on early-stage breast cancer. It involved 33 people with triple-negative or HER2-positive breast cancer. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Gustave Roussy
Villejuif, 94800, France
Conditions
Explore the condition pages connected to this study.